MedTrace Logo

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-05-09

No results posted yet for this study

Summary

This is an ascending dose escalation study to test the safety, tolerability and preliminary efficacy of ASN008 TG in first-in-human subjects

Conditions

  • Dermatitis, Atopic
  • Pruritus
  • Dermatitis Eczema

Interventions

DRUG

ASN008 TG

ASN008 TG

DRUG

Placebo TG

Placebo TG

Sponsors & Collaborators

  • Asana BioSciences

    lead INDUSTRY

Principal Investigators

  • Niranjan Rao, PhD · Asana BioSciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-14
Primary Completion
2020-03-20
Completion
2020-03-20
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03798561 on ClinicalTrials.gov